For example, in a patient with intentional overdose who is also on a GLP-1 agonist, the time to peak concentration of co-ingested agents may be prolonged, complicating risk assessment, decontamination decisions, and timing of antidotal therapies
Varias enfermedades y afecciones, como las enfermedades renales, las enfermedades del hgado graso, la resistencia a la insulina, las enfermedades neurodegenerativas, los trastornos de la fertilidad y los desequilibrios endocrinos, estn relacionadas con alteraciones del ciclo de la carnitina6
Rapid proliferation, high protein synthesis rates, hypoxia, nutrient deprivation, acidosis, and oxidative stress collectively impose a severe folding burden on the ER
Sexual health effects are increasingly documented
The process for a biosimilar GLP-1 has several distinct stages: Development and clinical testing The manufacturer conducts analytical studies, pharmacokinetic trials, and (in some cases) clinical immunogenicity studies to demonstrate biosimilarity to the reference product BLA submission A Biologics License Application is filed with the FDA, including all comparability data FDA review Typically 12 months from filing
The dose stays the same
